Novartis Aktie - NOT

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

105,98

( 0,99% )

Gebot

105,88

Fragen

105,90

Volumen

2.801

103,82 Tagesbereich 105,98

93,95 52-Wochen-Bereich 106,46

Marktkapitalisierung

224,47B

Handelsende

104,94

Handelsbeginn

104,44

Letzte Trade

105.98

Letzter Handelszeitpunkt

13:10:28

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

4.073

Ausgegebene Aktien

2.118.043.712

Dividendenrendite

3.08%

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

51,72B

Nettogewinn

11,94B

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.novartis.com

Hauptsitz

Basel, Che

Gegründet

Novartis AG is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker NOT. The last closing price for Novartis was 104,94 €. Over the last year, Novartis shares have traded in a share price range of 93,95 € to 106,46 €.

Novartis currently has 2.118.043.712 shares in issue. The market capitalisation of Novartis is 222,27 € billion.

Novartis receives approval for first malaria medicine for newborn babies and young infants

Novartis receives approval for first malaria medicine for newborn babies and young infants Coartem® (artemether-lumefantrine) Baby becomes first...

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) The GCAptAIN study did not meet its primary...

Novartis completes acquisition of Regulus Therapeutics

Novartis completes acquisition of Regulus Therapeutics Basel, June 25, 2025 – Novartis today announced that it has successfully completed its...

Novartis announces expiration of Regulus Therapeutics tender offer

Novartis announces expiration of Regulus Therapeutics tender offer Basel, June 25, 2025 – Novartis today announced that its previously announced...

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer Basel, June 23, 2025 – Novartis today announced the...

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH In...

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	2	1.9234468167	103.98	106.46	103.1	4586	104.27896289	DE
4	3.18	3.09338521401	102.8	106.46	100.12	4113	103.23539359	DE
12	6.98	7.05050505051	99	106.46	93.95	4073	101.09144217	DE
26	6.98	7.05050505051	99	106.46	93.95	4073	101.09144217	DE
52	6.98	7.05050505051	99	106.46	93.95	4073	101.09144217	DE
156	6.98	7.05050505051	99	106.46	93.95	4073	101.09144217	DE
260	25.64	31.9143639532	80.34	106.46	80.34	3992	101.09144217	DE

NOT - Frequently Asked Questions (FAQ)

What is the current Novartis share price?

The current share price of Novartis is 105,98 €

How many Novartis shares are in issue?

Novartis has 2.118.043.712 shares in issue

What is the market cap of Novartis?

The market capitalisation of Novartis is EUR 222,27B

What is the 1 year trading range for Novartis share price?

Novartis has traded in the range of 93,95 € to 106,46 € during the past year

What is the reporting currency for Novartis?

Novartis reports financial results in USD

What is the latest annual turnover for Novartis?

The latest annual turnover of Novartis is USD 51,72B

What is the latest annual profit for Novartis?

The latest annual profit of Novartis is USD 11,94B

What is the registered address of Novartis?

The registered address for Novartis is PO BOX, BASEL, 4002

What is the Novartis website address?

The website address for Novartis is www.novartis.com

Which industry sector does Novartis operate in?

Novartis operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
50C0BIT Mining Ltd	7,95 € (278,57%)	13,55k
KU9WK Kellogg Co	22,47 € (50,30%)	31,16k
IGS1IGC Pharma Inc	0,462 € (47,13%)	7,24k
55H0MP Materials Corporation	37,00 € (43,97%)	13,51k
L7C2Windfall Geotek Inc	0,0115 € (43,75%)	10,88k
MAH0Mereo Biopharma Group Plc	1,62 € (-35,20%)	20,4k
EUSKore Mining Ltd	0,0095 € (-34,48%)	1,3k
2DV0Drone Volt	0,878 € (-30,65%)	373,94k
7BC0Forte Group Holdings Inc	0,091 € (-26,61%)	1,13k
UP0Ultragenyx Pharmaceutical Inc	27,40 € (-22,60%)	376
ABBVolatus Aerospace Inc	0,482 € (25,52%)	16,64M
N04NuCana plc	0,061 € (15,09%)	12,37M
D7GNel ASA	0,2424 € (2,45%)	4,24M
4BHClara Technologies Corp	7,60 € (-21,65%)	3,65M
DRHDroneShield Limited	1,476 € (2,50%)	1,45M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Novartis AG (NOT)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Novartis AG

NOT Neueste Nachrichten

Novartis receives approval for first malaria medicine for newborn babies and young infants

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Novartis completes acquisition of Regulus Therapeutics

Novartis announces expiration of Regulus Therapeutics tender offer

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

NOT - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Novartis AG (NOT) Börsenkurse

Novartis AG (NOT)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Novartis AG

NOT Neueste Nachrichten

Novartis receives approval for first malaria medicine for newborn babies and young infants

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Novartis completes acquisition of Regulus Therapeutics

Novartis announces expiration of Regulus Therapeutics tender offer

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

NOT - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Anmelden

Werbung entfernen